Overview
- A Rutgers–University of Sydney analysis of 60 online Ozempic reviews found many users kept taking the drug when it produced weight loss or reduced cravings despite unpleasant side effects.
- About 62% of reviewers reported gastrointestinal issues, while those with little weight change or non‑GI problems were more likely to discontinue treatment.
- An India Today investigation reported prescription‑less sales of GLP‑1 injectables such as Ozempic and Mounjaro in Delhi through pharmacies and online platforms.
- Medical guidance in the reporting stresses supervised care with tailored dosing, dietary support, and regular follow‑up to manage common side effects and safeguard patients.
- Coverage highlights substantial weight‑loss and cardiometabolic benefits seen in trials, alongside cautions about rarer risks and contraindications including pancreatitis and certain thyroid cancer histories.